Data disclosure in Zambia

Owas Mwape Council Member Data Disclosure in Zambia MeTA 18/01/10

Type of data being collected
Policies, practices and results on
Registration
Availability
Pricing
Promotion
18/01/10 MeTA

Overview of disclosure process and engagement of stakeholders
How is the data being disclosed?
Data is being disclosed through interviews with key informants in the pharmaceutical sector
Are the stakeholders involved? How?
The stakeholders are involved in the process both as data collectors and as key informants
18/01/10 MeTA

Challenges & lessons Learned
Brief overview of the main challenges
Bureaucracy
Unavailability of key informants
Unavailability of data (publications, etc)
General suspicion (why is this information being collected)
General lack of transparency in the medical field (confidentiality seems to apply in the sector)
Common view that the public lack interest in such matters and therefore there is no need for information to be in the public domain
What are the lessons learned so far?
There is need for increased lobbying for full data disclosure in pharmaceutical sector
Need for full commitment to MeTA principles from stakeholders
Bureaucracy is still a major challenge!!!!
18/01/10 MeTA

Type of support needed
Strategies for ensuring full commitment of all stakeholders to the MeTA principle of increased transparency
MeTA International to advise on how other countries have managed to link up to up to the national health reform process with health summits and joint evaluation
18/01/10 MeTA

Thank you!
Owas Mwape
oramwa@yahoo.com/
+260 955 857 161
18/01/10 MeTA

Data disclosure in Zambia

by MeTApresents

Accessibility

Categories

Upload Details

Usage Rights

1 Embed 5

Statistics

Data disclosure in Zambia Presentation Transcript